Results 111 to 120 of about 2,191 (125)

Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib

Journal of Thoracic Oncology, 2023
Alexander Drilon, Yonina R Murciano-Goroff, Alexia E. Iasonos   +2 more
exaly  

Review of Synthetic Routes and Crystalline Forms of the Oncology Drugs Capmatinib, Selpercatinib, and Pralsetinib

Organic Process Research and Development, 2021
David Hughes
exaly  

Structural investigations, quantum mechanical studies on proton and metal affinity and biological activity predictions of selpercatinib

Journal of Molecular Liquids, 2021
Fahad Ahmed Al-Harthi, Utsab Bhattacharyya, Renjith Thomas   +2 more
exaly  

An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)

Journal of Oncology Pharmacy Practice, 2023
Marc Geirnaert
exaly  

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect

International Journal of Molecular Sciences, 2023
Michael C Kreissl, Daniela Grimm, Markus Wehland   +2 more
exaly  

Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors

Expert Review of Anticancer Therapy, 2023
Bhavana Konda, Dat Le
exaly  

Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve RET-Mutant Medullary Thyroid Cancer

Future Oncology, 2022
exaly  

Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.

Journal of Clinical Endocrinology and Metabolism
Erminia Massarelli, Roderick Clifton-Bligh, Lori J Wirth   +2 more
exaly  

Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001

Cancers
Filippo de Braud, Barbara Deschler-Baier, Min-Hua Jen   +2 more
exaly  

Top bar navigation

Frontiers in Pharmacology
Qiong Jie
exaly